Haier Biomedical Advances Integrated Biopharma Infrastructure

From August 20-21, Haier Biomedical presented its automated biostorage and connected pharmaceutical systems at the ISPE Singapore Conference & Exhibition 2026. The company used the major Asian pharmaceutical engineering event, held at Suntec Singapore, to launch its automated -80°C storage solution to an international audience. This debut signaled a significant strategic evolution for the company, which is moving from supplying individual pieces of equipment to delivering integrated, multi-category platforms for next-generation biopharmaceutical infrastructure. Haier Biomedical’s exhibit concentrated on solutions for pharmaceutical R&D, production, and quality control, with a clear emphasis on bringing automation and digital connectivity to these vital industry processes.

Overview

At ISPE Singapore 2026, Haier Biomedical (SHA: 688139) presented a full portfolio of automated and digital tools for the pharmaceutical sector. The collection covered R&D, production, and quality control. Its centerpiece was the international debut of an automated -80°C storage solution, a system that combines automated ultra-low-temperature storage with intelligent sample management to increase the efficiency and traceability of high-value biological materials. The company also featured a pilot freeze dryer, designed to help organizations scale up from laboratory research to full manufacturing by supporting process development and pilot-scale freeze-drying.

The company also hosted a Power Hour session to introduce its Smart RFID ULT Storage Solution. This platform forges a direct link between physical samples and their digital records. It uses unique RFID labels on each sample and compartment antennas that capture data without needing direct line-of-sight scanning. The system’s software then tracks the precise location and complete movement history for every sample, automatically generating structured records for all inbound and outbound activity. With adaptable interfaces, the platform can handle diverse sample formats, including bottles, bags, tubes, and cryovials. This level of connectivity eliminates manual searches and laborious inventory checks while creating a much stronger chain-of-custody across quality control, warehousing, and the entire supply chain. The company’s financial performance reflects this focus, with first-half 2026 revenue from pharmaceutical clients rising 23% year-over-year while laboratory solutions revenue grew by 19%. AI-related business expanded to represent 18% of total revenue, a 3-point increase from 2025.

Key Takeaways

• Haier Biomedical’s automated -80°C storage solution was launched internationally at ISPE Singapore 2026.
• The company displayed a new pilot freeze dryer to help bridge the gap between lab research and manufacturing.
• Its Smart RFID ULT Storage Solution links physical samples to digital records, improving sample tracking and cutting down on manual inventory work.
• In the first half of 2026, revenue from pharmaceutical customers grew 23% year-over-year.
• Laboratory solutions revenue saw 19% growth in the same period.
• AI-related business accounted for 18% of revenue in H1 2026, up from 15% in 2025.

Industry Implications

The systems Haier Biomedical unveiled in Singapore point to a powerful industry trend. Biopharmaceutical infrastructure is becoming more integrated and data-driven. For competitors, the strategic pivot away from standalone equipment toward comprehensive, scenario-specific product suites creates pressure to move beyond selling individual devices. The focus on automated ultra-low-temperature storage and intelligent RFID-based sample management is establishing a higher industry standard for sample integrity, traceability, and process efficiency from R&D through to quality control. Traditional equipment manufacturers must now develop more connected and interoperable systems or they will be outmaneuvered in a market that increasingly values complete solutions.

The market itself may be reshaped. Further consolidation or new strategic partnerships could emerge as companies race to offer end-to-end platforms instead of disconnected components. Haier Biomedical’s recent financial performance – with 23% growth in pharmaceutical revenue and 19% in laboratory solutions in H1 2026 – provides strong evidence of the market’s appetite for these advanced, digitally native systems. This shift is already changing customer behavior, prompting pharmaceutical firms and research institutions to find partners who can supply scalable R&D and production infrastructure built around automation and data-centric quality control. The downstream consequences could be significant, potentially leading to faster drug discovery timelines and lower operational costs by improving sample management and reducing manual errors in complex biopharma workflows.

Conclusion

Haier Biomedical’s exhibit at ISPE Singapore 2026 marked a decisive turn toward intelligent biopharmaceutical infrastructure. The company is no longer just selling equipment; it is offering integrated, automated platforms. The international launch of its automated -80°C storage system and the introduction of the Smart RFID ULT Storage Solution underscore a deep commitment to improving sample management, traceability, and efficiency across the entire pharmaceutical value chain. This strategy directly addresses the market’s growing demand for connected workflows that unite samples, devices, and data – a demand validated by the company’s impressive revenue growth in its core pharmaceutical and laboratory segments. By continuing to adapt its products to meet local regulations and specific customer requirements, Haier Biomedical is positioning itself to help build smarter and more scalable pharmaceutical systems around the world.